Citadel Advisors
KPTI icon

Citadel Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Citadel Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
249,300
+178,000
+250% +$1.36M ﹤0.01% 6895
2025
Q4 		$525K Buy
71,300
+25,000
+54% +$153K ﹤0.01% 8917
2025
Q3 		$303K Buy
+46,300
New +$249K ﹤0.01% 10357
2025
Q2 		– Sell
-10,798
Closed -$40.4K – 13901
2025
Q1 		$40.4K Buy
10,798
+9,631
+825% +$82.2K ﹤0.01% 12532
2024
Q4 		$11.8K Sell
1,167
-3,100
-73% -$37.5K ﹤0.01% 13527
2024
Q3 		$53.1K Sell
4,267
-1,040
-20% -$12.9K ﹤0.01% 11836
2024
Q2 		$69.1K Buy
5,307
+3,320
+167% +$55K ﹤0.01% 11389
2024
Q1 		$45K Buy
1,987
+394
+25% +$6.91K ﹤0.01% 12269
2023
Q4 		$20.7K Buy
1,593
+540
+51% +$7.28K ﹤0.01% 12596
2023
Q3 		$21.2K Buy
1,053
+926
+729% +$20.8K ﹤0.01% 12587
2023
Q2 		$3.4K Sell
127
-1,086
-90% -$46.8K ﹤0.01% 13696
2023
Q1 		$70.8K Sell
1,213
-4,527
-79% -$223K ﹤0.01% 11718
2022
Q4 		$293K Sell
5,740
-1,493
-21% -$103K ﹤0.01% 9372
2022
Q3 		$592K Sell
7,233
-114
-2% -$8.52K ﹤0.01% 8093
2022
Q2 		$497K Sell
7,347
-1,280
-15% -$117K ﹤0.01% 8670
2022
Q1 		$954K Sell
8,627
-4,373
-34% -$545K ﹤0.01% 7811
2021
Q4 		$1.25M Buy
13,000
+2,627
+25% +$262K ﹤0.01% 7379
2021
Q3 		$906K Buy
10,373
+6,960
+204% +$722K ﹤0.01% 8409
2021
Q2 		$528K Buy
3,413
+1,513
+80% +$220K ﹤0.01% 9943
2021
Q1 		$300K Sell
1,900
-1,240
-39% -$261K ﹤0.01% 10859
2020
Q4 		$729K Sell
3,140
-4,907
-61% -$1.14M ﹤0.01% 7434
2020
Q3 		$1.76M Buy
8,047
+400
+5% +$97.8K ﹤0.01% 4956
2020
Q2 		$2.17M Sell
7,647
-1,413
-16% -$418K ﹤0.01% 4419
2020
Q1 		$2.61M Buy
9,060
+67
+0.7% +$18.5K ﹤0.01% 3693
2019
Q4 		$2.59M Buy
8,993
+6,353
+241% +$1.38M ﹤0.01% 4012
2019
Q3 		$381K Buy
2,640
+1,020
+63% +$138K ﹤0.01% 7209
2019
Q2 		$146K Sell
1,620
-2,267
-58% -$182K ﹤0.01% 8370
2019
Q1 		$340K Buy
3,887
+1,334
+52% +$148K ﹤0.01% 7428
2018
Q4 		$359K Buy
2,553
+1,020
+67% +$172K ﹤0.01% 6951
2018
Q3 		$392K Buy
+1,533
New +$424K ﹤0.01% 7111
2018
Q2 		– Sell
-953
Closed -$192K – 9076
2018
Q1 		$192K Buy
+953
New +$190K ﹤0.01% 7383
2017
Q4 		– Sell
-1,060
Closed -$175K – 8229
2017
Q3 		$175K Buy
+1,060
New +$152K ﹤0.01% 6782
2017
Q2 		– Sell
-1,273
Closed -$245K – 7802
2017
Q1 		$245K Buy
+1,273
New +$204K ﹤0.01% 6195
2016
Q3 		– Sell
-1,160
Closed -$117K – 7499
2016
Q2 		$117K Buy
1,160
+200
+21% +$26K ﹤0.01% 6127
2016
Q1 		$128K Buy
960
+687
+252% +$75.8K ﹤0.01% 5913
2015
Q4 		$54K Sell
273
-134
-33% -$29K ﹤0.01% 7246
2015
Q3 		$64K Sell
407
-153
-27% -$40.9K ﹤0.01% 7388
2015
Q2 		$229K Buy
560
+393
+235% +$170K ﹤0.01% 6139
2015
Q1 		$77K Sell
167
-266
-61% -$115K ﹤0.01% 7065
2014
Q4 		$243K Buy
433
+60
+16% +$34.1K ﹤0.01% 5735
2014
Q3 		$196K Buy
+373
New +$211K ﹤0.01% 5745

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citadel Advisors's KPTI Position: Q1 2026 in Review

Citadel Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 31,709 shares — an estimated $242K sold.

Citadel Advisors first reported a position in KPTI in Q2 2014 and held it in 43 quarters. The position peaked at $28.9M in Q1 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Citadel Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 31,709 Karyopharm Therapeutics shares in Q1 2026, an estimated $242K.
  • Citadel Advisors first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 43 quarters.
  • Citadel Advisors's Karyopharm Therapeutics position peaked at $28.9M in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.